These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 1997493

  • 1. Effects of percent thresholding on the extraction of [18F]fluorodeoxyglucose positron emission tomographic region-of-interest data.
    Rottenberg DA, Moeller JR, Strother SC, Dhawan V, Sergi ML.
    J Cereb Blood Flow Metab; 1991 Mar; 11(2):A83-8. PubMed ID: 1997493
    [Abstract] [Full Text] [Related]

  • 2. Fluorine-18-fluorodeoxyglucose PET to determine regional cerebral glucose utilization: a re-examination.
    Schmidt KC, Lucignani G, Sokoloff L.
    J Nucl Med; 1996 Feb; 37(2):394-9. PubMed ID: 8667082
    [No Abstract] [Full Text] [Related]

  • 3. Methodologic factors affecting PET measurements of cerebral glucose metabolism.
    Jagust WJ, Budinger TF, Huesman RH, Friedland RP, Mazoyer BM, Knittel BL.
    J Nucl Med; 1986 Aug; 27(8):1358-61. PubMed ID: 3488379
    [Abstract] [Full Text] [Related]

  • 4. Regional kinetic constants and cerebral metabolic rate for glucose in normal human volunteers determined by dynamic positron emission tomography of [18F]-2-fluoro-2-deoxy-D-glucose.
    Heiss WD, Pawlik G, Herholz K, Wagner R, Göldner H, Wienhard K.
    J Cereb Blood Flow Metab; 1984 Jun; 4(2):212-23. PubMed ID: 6609929
    [Abstract] [Full Text] [Related]

  • 5. Measurement of regional cerebral glucose utilization with fluorine-18-FDG and PET in heterogeneous tissues: theoretical considerations and practical procedure.
    Lucignani G, Schmidt KC, Moresco RM, Striano G, Colombo F, Sokoloff L, Fazio F.
    J Nucl Med; 1993 Mar; 34(3):360-9. PubMed ID: 8441024
    [Abstract] [Full Text] [Related]

  • 6. [18F-fluorodeoxyglucose positron emission tomography in Parkinson's disease].
    Arahata Y, Kato T, Tadokoro M, Sobue G.
    Nihon Rinsho; 1997 Jan; 55(1):222-6. PubMed ID: 9014454
    [Abstract] [Full Text] [Related]

  • 7. Peptide T and glucose metabolism in AIDS dementia complex.
    Villemagne VL, Phillips RL, Liu X, Gilson SF, Dannals RF, Wong DF, Harris PJ, Ruff M, Pert C, Bridge P, London ED.
    J Nucl Med; 1996 Jul; 37(7):1177-80. PubMed ID: 8965193
    [Abstract] [Full Text] [Related]

  • 8. Dynamic [18F]fluorodeoxyglucose positron emission tomography and hypometabolic zones in seizures: reduced capillary influx.
    Cornford EM, Gee MN, Swartz BE, Mandelkern MA, Blahd WH, Landaw EM, Delgado-Escueta AV.
    Ann Neurol; 1998 Jun; 43(6):801-8. PubMed ID: 9629850
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The metabolic pathology of the AIDS dementia complex.
    Rottenberg DA, Moeller JR, Strother SC, Sidtis JJ, Navia BA, Dhawan V, Ginos JZ, Price RW.
    Ann Neurol; 1987 Dec; 22(6):700-6. PubMed ID: 3501695
    [Abstract] [Full Text] [Related]

  • 11. Effect of gender on glucose utilization rates in healthy humans: a positron emission tomography study.
    Miura SA, Schapiro MB, Grady CL, Kumar A, Salerno JA, Kozachuk WE, Wagner E, Rapoport SI, Horwitz B.
    J Neurosci Res; 1990 Dec; 27(4):500-4. PubMed ID: 2079712
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. PET studies of cerebral glucose metabolism in conscious rhesus macaques.
    Eberling JL, Roberts JA, De Manincor DJ, Brennan KM, Hanrahan SM, Vanbrocklin HF, Roos MS, Jagust WJ.
    Neurobiol Aging; 1995 Dec; 16(5):825-32. PubMed ID: 8532117
    [Abstract] [Full Text] [Related]

  • 16. The metabolic topography of normal aging.
    Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Mandel F, Alexander GE, Grady C, Pietrini P, Eidelberg D.
    J Cereb Blood Flow Metab; 1996 May; 16(3):385-98. PubMed ID: 8621743
    [Abstract] [Full Text] [Related]

  • 17. Reversal of brain metabolic abnormalities following treatment of AIDS dementia complex with 3'-azido-2',3'-dideoxythymidine (AZT, zidovudine): a PET-FDG study.
    Brunetti A, Berg G, Di Chiro G, Cohen RM, Yarchoan R, Pizzo PA, Broder S, Eddy J, Fulham MJ, Finn RD.
    J Nucl Med; 1989 May; 30(5):581-90. PubMed ID: 2785582
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Cerebral glucose metabolism in dementia (PET-FDG study)].
    Hatazawa J, Itoh M, Matsuzawa T.
    Rinsho Hoshasen; 1989 Oct; 34(11):1343-8. PubMed ID: 2601096
    [Abstract] [Full Text] [Related]

  • 20. Simplified calculation of MRglc using PET.
    Phillips RL, London ED.
    J Nucl Med; 1997 Aug; 38(8):1334. PubMed ID: 9255178
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.